1. European Commission. MEMO/08/782, Brussels, 10 December 2008. Strengthening pharmacovigilance to reduce adverse effects of medicine. Available at:
http://europa.eu/rapid/press-release_MEMO-08-782_en.htm?locale=en
. Accessed 1 Feb 2018.
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329:15–9.
3. Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European union pharmacovigilance system works. Drug Saf. 2017;40(10):855–69.
4. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010. Available at:
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF
. Accessed 22 Nov 2017.
5. Šarinić VM, Dimov Di Giusti M, Banovac M, Skvrce NM, Gvozdanović K, Krnić D, et al. SCOPE Work Package 4 survey report. Available at:
http://www.scopejointaction.eu/_assets/files/SCOPE-WP4-Topic-1,2,5-survey-report.pdf
. Accessed 22 Nov 2017.